Details of the Drug

General Information of Drug (ID: DMG65WH)

Drug Name

Ficlatuzumab

Synonyms

AV-299

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Pancreatic cancer	2C10	Phase 2	[2]
Squamous cell carcinoma	2B60-2D01	Phase 2	[2]
Acute myeloid leukaemia	2A60	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Multiple myeloma

ICD Disease Classification

2A83

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Hepatocyte growth factor (HGF)	DTT	HGF	4.90E-01	0.13	2.73
Hepatocyte growth factor (HGF)	DTT	HGF	1.98E-07	1.58	2.92

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)